Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito


N. 45 (2016)

Terapia del dolore severo e dipendenza in Italia: il ruolo di FeDerSerD

  • Pietro Fausto D'Egidio
  • Felice Nava
  • Guido Faillace
  • Marco Riglietta
  • Alfio Lucchini
  • Gruppo di lavoro nazionale FeDerSerD "Terapia del dolore e dipendenze"
21 April 2017

Riferimenti bibliografici

  1. Passik S.D. (2009), “Issues in Long-term Opioid Therapy: Unmet Needs, Risks, and Solutions”, Mayo Clin Proc, Jul, 84(7): 593-601.
  2. Denisco R.A., Chandler R.K., Compton W.M. (2008), “Addressing the intersecting problems of opioid misuse and chronic pain treatment”, Exp Clin Psychopharmacol, Oct, 16(5): 417-28.
  3. Maremmani I., Gerra G., Ripamonti I.C., Mugelli A., Allegri M., Viganò R. et al. (2015), “The prevention of analgesic opioids abuse: expert opinion”, Eur Rev Med Pharmacol Sci, Nov, 19(21): 4203-6.
  4. Leonardi C., Vellucci R., Mammucari M., Fanelli G. (2015), “Opioid risk addiction in the management of chronic pain in primary care: the addition risk questionnaire”, Eur Rev Med Pharmacol Sci, Dec, 19(24): 4898-905.
  5. Cicero T.J., Inciardi J.A., Muñoz A. (2005), “Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004”, J Pain Off J Am Pain Soc, Oct, 6(10): 662-72.
  6. Dart R.C., Surratt H.L., Cicero T.J., Parrino M.W., Severtson S.G., Bucher-Bartelson B. et al. (2015), “Trends in Opioid Analgesic Abuse and Mortality in the United States”, N Engl J Med, Jan 15, 372(3): 241-8.
  7. Strassels S.A. (2009), “Economic burden of prescription opioid misuse and abuse”, J Manag Care Pharm JMCP, Sep, 15(7): 556-62.
  8. Garland E.L., Froeliger B., Zeidan F., Partin K., Howard M.O. (2013), “The Downward Spiral of Chronic Pain, Prescription Opioid Misuse, and Addiction: Cognitive, Affective, and Neuropsychopharmacologic Pathways”, Neurosci Biobehav Rev, Dec, 37(10 0 2): 2597-607.
  9. Weissman D.E. (1993), “Doctors, opioids, and the law: the effect of controlled substances regulations on cancer pain management”, Semin Oncol, Apr, 20(2 Suppl 1): 53-8.
  10. Hill C.S. (1993), “The barriers to adequate pain management with opioid analgesics”, Semin Oncol, Apr, 20(2 Suppl 1): 1-5.
  11. Lebovits A.H., Florence I., Bathina R., Hunko V., Fox M.T., Bramble C.Y. (1997), “Pain knowledge and attitudes of healthcare providers: practice characteristic differences”, Clin J Pain, Sep, 13(3): 237-43.
  12. Budman S.H., Grimes Serrano J.M., Butler S.F. (2009), “Can abuse deterrent formulations make a difference? Expectation and speculation”, Harm Reduct J, 6: 8.
  13. FDA/CDER (2015), Guidance for Industry: Abuse-Deterrent Opioids- Evaluation and Labeling.
  14. World Health Organization. World report on child injury prevention [Internet]. WHO [cited 2016 Mar 7]. Available from:
  15. Burghardt L.C., Ayers J.W., Brownstein J.S., Bronstein A.C., Ewald M.B., Bourgeois F.T. (2013), “Adult Prescription Drug Use and Pediatric Medication Exposures and Poisonings”, Pediatrics, May 1, peds. 2012-978.
  16. RCP PecFent [Internet] [cited 2016 Mar 16]. Available from:
  17. Walton W.W. (1982), “An evaluation of the Poison Prevention Packaging Act”, Pediatrics, Mar, 69(3): 363-70.
  18. Rodgers G.B. (1996), “The safety effects of child-resistant packaging for oral prescription drugs. Two decades of experience”, JAMA, Jun 5, 275(21): 1661-5.
  19. National Coordinating Council for Medication Error Reporting and Prevention. About Medication Errors [Internet]. NCC MERP. 2014 [cited 2016 Mar 11]. Available from:
  20. Lavon O., Ben-Zeev A., Bentur Y. (2014), “Medication errors outside healthcare facilities: a national poison centre perspective”, Basic Clin Pharmacol Toxicol, Mar, 114(3): 288-92.
  21. Berman A. (2004), “Reducing medication errors through naming, labeling, and packaging”, J Med Syst, Feb, 28(1): 9-29.
  22. Pakenham-Walsh N., Ana J. (2014), “Confusing drug packaging contributes to death of 15 children”, Lancet Glob Health, Nov, 2(11): e634.
  23. Centers for Disease Control and Prevention (2016), Guideline for Prescribing Opioids for Chronic Pain.
  24. Panerai A.E. (2009), “L’associazione a dose fissa ossicodone/paracetamolo nel trattamento del dolore cronico non neoplastico”, Trends Med, 9(1): 27-35.
  25. U.S. Food and Drug Administration C for DE and Information by Drug Class, Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids [Internet] [cited 2016 Mar 11]. Available from:
  26. RCP Contramal [Internet] [cited 2016 Mar 16]. Available from:
  27. RCP Palexia [Internet] [cited 2016 Mar 16]. Available from:
  28. RCP Oxycontin [Internet] [cited 2016 Mar 16]. Available from:
  29. RCP Co-Efferalgan [Internet] [cited 2016 Mar 16]. Available from:
  30. RCP Depalgos [Internet] [cited 2016 Mar 16]. Available from:
  31. Streisand J.B., Zhang J., Niu S., McJames S., Natte R., Pace N.L. (1995), “Buccal absorption of fentanyl is pH-dependent in dogs”, Anesthesiology, Mar, 82(3): 759-64.
  32. Jham B.C., da Silva Freire A.R. (2006), “Oral complications of radiotherapy in the head and neck”, Braz J Otorhinolaryngol, Oct, 72(5): 704-8.
  33. Davies A., Mundin G., Vriens J., Webber K., Buchanan A., Waghorn M. (2016), “The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain”, J Pain Symptom Manage, Mar, 51(3): 538-45.
  34. Taylor D., Radbruch L., Revnic J., Torres L.M., Ellershaw J.E., Perelman M. (2014), “A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain”, J Pain Symptom Manage, Jun, 47(6): 1001-7.


Caricamento metriche ...